Page last updated: 2024-11-11

2-cyano-3-(1-phenylindol-3-yl)acrylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-cyano-3-(1-phenylindol-3-yl)acrylate: inhibits pyruvate transport into mitochondria [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438504
CHEMBL ID4303684
SCHEMBL ID16620642
MeSH IDM0128325

Synonyms (36)

Synonym
uk-5099
uk 5099
56396-35-1
2-propenoic acid, 2-cyano-3-(1-phenyl-1h-indol-3-yl)-
uk5099
2-cpiya
(e)-2-cyano-3-(1-phenylindol-3-yl)prop-2-enoic acid
HY-15475
CS-1048 ,
alpha-cyano-beta-(1-phenylindol-3-yl)acrylate
2-cyano-3-(1-phenylindol-3-yl)acrylate
BCPP000027
2-cyano-3-(1-phenyl-1h-indol-3-yl)-2-propenoic acid
pf-1005023
S5317
2-cyano-3-(1-phenyl-1h-indol-3-yl)-acrylic acid
AKOS024458020
SCHEMBL16620642
2-cyano-3-(1-phenyl-1h-indol-3-yl)prop-2-enoic acid
AS-63568
i2r ,
uk-5099, >=98% (hplc)
(e)-2-cyano-3-(1-phenyl-1h-indol-3-yl)acrylic acid
2260696-90-8
2-cyano-3-(1-phenyl-1h-indol-3-yl)acrylic acid
A12644
CCG-267359
CHEMBL4303684
alpha-cyano-beta-(1-phenylindol-3-yl)-acrylate
gtpl11302
nsc784390
nsc-784390
uk5099; pf-1005023
EX-A1928
2-cyano-3-(1-phenyl-1h-indol-3-yl)acrylicacid
AC-36255

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This study was the first report of the pharmacokinetic parameters of UK-5099 in mice, which will help to further study the administration of UK-5099 in animals and humans."( Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC-MS/MS.
Lv, K; Mo, J; Si, H; Wang, X; Yan, B; Zeng, Q; Zhang, J, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1708853Inhibition of MPC in human MCF-10A cells assessed as increase in cellular lactate production incubated for 24 to 30 hrs2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss.
AID1708852Inhibition of MPC in human MCF-10A cells assessed as increase in cellular lactate production at 10 uM incubated for 24 to 30 hrs2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss.
AID1708855Inhibition of MPC in human MCF-10A cells assessed as reduction in oxygen consumption rate using pyruvate and malate and ADP2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (10.00)18.7374
1990's5 (16.67)18.2507
2000's1 (3.33)29.6817
2010's13 (43.33)24.3611
2020's8 (26.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.52 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index5.95 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]